Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
598 studies found for:    Open Studies | "Ovarian Diseases"
Show Display Options
Rank Status Study
21 Not yet recruiting Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome
Condition: OHSS
Interventions: Drug: Cabergoline;   Drug: Calcium gluconate
22 Not yet recruiting A Phase II Study Of Nivolumab/ Bevacizumab
Conditions: Peritoneal Cancer;   Ovarian Cancer;   Fallopian Tube Cancer
Interventions: Drug: Bevacizumab;   Drug: Nivolumab
23 Not yet recruiting PET Imaging of Ovarian Carcinoma With 18F-FSPG
Conditions: Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Radiation: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG);   Procedure: Positron Emission Tomography;   Other: Laboratory Biomarker Analysis
24 Not yet recruiting Pubertal Induction in Individuals With Hypogonadism
Conditions: Primary Amenorrhoea;   Hypothalamic Amenorrhoea;   Hypogonadotrophic Hypogonadism;   Hypopituitarism;   Turner's Syndrome;   Primary Ovarian Insufficiency
Intervention: Drug: Routine transdermal oestrogen patch
25 Not yet recruiting Evaluation of Adipokines in Obese and Non-obese Egyptian Women With Polycystic Ovary Syndrome
Condition: Polycystic Ovarian Syndrome
Intervention:
26 Recruiting Institut Paoli Calmettes Ovarian Cancer Database
Condition: Ovarian Neoplasms
Intervention: Other: Data collection
27 Recruiting Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Apatinib;   Drug: Etoposide
28 Recruiting The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS
Condition: Polycystic Ovary Syndrome
Interventions: Drug: Metformin;   Drug: ethinyl estradiol and cyproterone acetate
29 Recruiting MLE4901 vs. Placebo for the Treatment of PCOS
Condition: Polycystic Ovary Syndrome (PCOS)
Interventions: Drug: MLE4901 40mg;   Drug: MLE4901 60mg;   Drug: MLE4901 80mg;   Drug: Placebo
30 Not yet recruiting Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Pembrolizumab;   Drug: Pegylated Liposomal Doxorubicin (PLD)
31 Not yet recruiting Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction
Conditions: Female Sexual Dysfunction;   Polycystic Ovary Syndrome
Interventions: Dietary Supplement: Vitamin D;   Drug: Hormonal contraception
32 Recruiting Intra-peritoneal Chemotherapy in Ovarian Cancer
Conditions: Ovarian Neoplasms;   Immune Tolerance;   Neoplasms;   Effects of Chemotherapy
Intervention:
33 Recruiting Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions: Procedure: Upfront cytoreductive surgery;   Procedure: Interval debulking surgery
34 Recruiting ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Chemotherapy;   Drug: Rucaparib
35 Not yet recruiting Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Olaparib;   Drug: Cediranib;   Drug: Platinum-based Chemotherapy
36 Not yet recruiting Cost Utility of Radical Surgery in Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Other: Collection of additional data with questionnaires
37 Recruiting Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
38 Recruiting The Effect of Surgery for Non Endometriosic Ovarian Cysts on Ovarian Reserve
Conditions: Antimullerian Hormone;   Ovarian Cysts;   Antral Follicle Count
Intervention:
39 Recruiting Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Interventions: Device: Cryosurgery;   Biological: NK immunotherapy
40 Not yet recruiting Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome
Condition: Ovarian Hyperstimulation Syndrome
Interventions: Drug: bromocriptine;   Drug: dexamethasone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years